Prescription Migraine Medicine segmentation by type groups agents into distinct pharmacologic classes, each reflecting a different mechanism of action and market dynamics. Triptans remain the most established abortive class, comprising sumatriptan, rizatriptan, and newer formulations; they generate the bulk of acute‑treatment volume but face competition from emerging CGRP antagonists. Calcitonin‑gene‑related peptide (CGRP) receptor antagonists—including ubrogepant, rimegepant, and atogepant—have rapidly captured market share owing to oral availability and favorable safety profiles, expanding both acute and preventive portfolios. Ditans, represented by lasmiditan, occupy a niche for patients contraindicated for triptans, contributing modest revenue but offering differentiation. Ergot derivatives such as dihydroergotamine retain limited use, primarily in refractory cases, and thus represent a marginal share. Monoclonal antibodies targeting CGRP or its receptor (e.g., erenumab, fremanezumab) dominate the preventive segment, commanding premium pricing and driving growth in long‑term therapy. NSAID‑combination products serve as adjuncts, supporting overall consumption but accounting for a small fraction of sales. The composite of these types defines the market taxonomy and informs competitive positioning across the prescription migraine landscape.
